Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Earlier this month full Phase 3 data presented at the American Diabetes Association conference showed participants on the highest dose losing an average of 28.3% of their body weight over 80 weeks, with Lilly Chief Scientific and Product Officer Dan Skovronsky describing that level of weight loss as previously the exclusive territory of bariatric surgery
The dose-response relationship remained consistent throughout treatment
Sudhof TC
Timothy Garvey discussed the results of a study leveraging data from STEP 1 and STEP 4 to determine the reduction in 10-year risk of type 2 diabetes seen with use of semaglutide 2.4 mg vs placebo therapy
37 LappartientA
US$ 29.56
US$ 24.54
US$ 28.12
US$ 26.24
